ArticleJournal of translational medicine2022
Dysbiosis of vaginal microbiota associated with persistent high-risk human papilloma virus infection.
Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Associations of Atopobium, Garderella, Megasphaera, Prevotella, Sneathia, and Streptococcus with human papillomavirus infection, cervical intraepithelial neoplasia, and cancer: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Leveraging existing 16S rRNA gene surveys to decipher microbial signatures and dysbiosis in cervical carcinogenesis.Scientific reports · 2024Pooled it
- Disturbances of Vaginal Microbiome Composition in Human Papillomavirus Infection and Cervical Carcinogenesis: A Qualitative Systematic Review.Frontiers in oncology · 2022Pooled it
- Effectiveness of vaginal probioticsAging · 2024Trial
- Harnessing the Vaginal Microbiome: A New Frontier in the Prevention of Sexually Transmitted Infections.Expert reviews in molecular medicine · 2026Review
- Vaginal microbiome and inflammation cytokines among Chinese women.NPJ biofilms and microbiomes · 2026Article
- Comment on "Effect of Vaginal Microecological Alterations on Female Pelvic Organ Prolapse".International urogynecology journal · 2026Article
- Characterization of Monomeric and Dimeric Forms of the Lectin TFF1 in the Human Vagina: Possible Role for the Innate Immune Defence.International journal of molecular sciences · 2026Article
- Prevalence and Co-occurrence of Candida albicans and Sexually Transmitted Infections in Lactobacillus-Deficient HIV-Negative Adolescent Girls and Young women.Mycopathologia · 2026Article
- Review
- The hormone-microbiota-NET framework in gynecologic diseases: evidence, controversies, and translational opportunities.Frontiers in immunology · 2026Review
- Vaginal microecological diversity and Ureaplasma urealyticum co-infection in high-risk HPV infection: a cross-sectional study.Frontiers in cellular and infection microbiology · 2026Article
- Targeting vaginal dysbiosis: prospects for the application of live biotherapeutics products.Frontiers in microbiology · 2026Review
- Integrating microbiome insights into cervical cancer.Frontiers in medicine · 2026Review
- Vaginal Microecological Imbalance, Human Papillomavirus Infection, and Cervical Carcinogenesis: Mechanisms and Clinical Implications.International journal of general medicine · 2026Review
- From dysbiosis to mechanisms: Why cervicovaginal microbiome-HPV studies must catch up with biology.PLoS pathogens · 2025Article
- Review
- The dual role of vulvovaginal candidiasis in HPV infection: implications for vaginal microecology and cervical lesions.Frontiers in microbiology · 2025Review
- Understanding the role of oral and vaginal microbiomes in HPV-related cervical, head, and neck cancers: knowledge gaps and feasibility in Sub-Saharan Africa.Frontiers in microbiomes · 2025Review
- Human papillomavirus molecular prevalence in south China and the impact on vaginal microbiome of unvaccinated women.mSystems · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe status of vaginal microbiota in persistent high-risk human papilloma virus (HR-HPV) infection is unclear. The present work aimed to identify the vaginal microbiota of persistent HPV infection and explore the possible underlying microbiota factors.
methodsA total of 100 women were recruited in this study, of which 28 presented HR-HPV persistent infection (P group), 30 showed clearance of any subtype of HR-HPV (C group), and 42 had no history of any HR-HPV infection (NC group). The vaginal microbiota and the community structure of the three groups were compared based on the 16S rRNA sequencing of the V3-V4 region. The microbiota diversity and differential analysis were carried out to detect the potential factors associated with HR-HPV infection.
resultsP and C groups showed an increase of Firmicutes and Actinobacteriota but a decrease in Proteobacteria compared to the NC group. The Chao1 index indicated that the microbial richness of the NC group was greater than C group (P < 0.05).The principal co-ordinate analysis(PCoA) revealed differences between the NC and P/C groups.The linear discriminant analysis effect size (LEfSe) method indicated that Proteobacteria phylum was significantly different in the mean relative abundance in the NC group,but the P and C groups did not show such indicative taxa. The Wilcox rank-sum test indicated that the Bifidobacterium (P = 0.002) and Lactobacillus (P = 0.005) of the C group were in a high mean relative abundance compared to the NC group.
conclusionsThe persistent HR-HPV infection is associated with dysbiosis of the vaginal microbiota. Microbiome regulation with Bifidobacteria and Lactobacillus may affect the clearance of HPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.